A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
==== Analysis of biological fluids ==== The GC-EI-MS can be incorporated for the analysis of biological fluids for several applications. One example is the determination of thirteen synthetic pyrethroid insecticide molecules and their stereoisomers in whole blood. This investigation used a new rapid and sensitive electron ionization-gas chromatography–mass spectrometry method in selective ion monitoring mode (SIM) with a single injection of the sample. All the pyrethroid residues were separated by using a GC-MS operated in electron ionization mode and quantified in selective ion monitoring mode. The detection of specific residues in blood is a difficult task due to their very low concentration since as soon as they enter the body most of the chemicals may get excreted. However, this method detected the residues of different pyrethroids down to the level 0.05–2 ng/ml. The detection of this insecticide in blood is very important since an ultra-small quantity in the body is enough to be harmful to human health, especially in children. This method is a very simple, rapid technique and therefore can be adopted without any matrix interferences. The selective ion monitoring mode provides detection sensitivity up to 0.05 ng/ml. Another application is in protein turnover studies using GC-EI-MS. This measures very low levels of d-phenylalanine which can indicate the enrichment of amino acid incorporated into tissue protein during studies of human protein synthesis.
The US had been bombing nearby telecommunications antennas, according to the victim's relative. According to the Department of Defense, seven US soldiers were injured and expected to survive. The soldiers suffered shrapnel and gunfire wounds. During the 2026 State of the Union Address, Trump awarded the Medal of Honor to Chief Warrant Officer Eric Slover, one of the helicopter pilots that got injured during the operation. Slover was the lead Chinook pilot for the air assault element of the operation. His helicopter came under fire as the flight approached Maduro's compound, and he was hit in the leg and hip by four bullets. His aircraft was also hit but remained flyable. Despite his wounds, Slover maintained control of the aircraft and got the Delta Team onboard over the compound and allowed them to fast rope to the ground. He then flew back to the USS Iwo Jima located in the Caribbean Sea.
=== Education === Kenyon graduated with honors from the University of Chicago with a Bachelor of Science in physics in 1961 as a member of Phi Beta Kappa. As an undergraduate, he developed an interest in origin of life research after attending the Darwin Centennial Celebration in 1959. He then earned his Ph.D. in biophysics from Stanford University in 1965. His doctoral dissertation was titled, "Photochemistry of DL-phenylalanine". After receiving his doctorate, he completed research as a postdoctoral fellow of the National Science Foundation in chemical biodynamics at the University of California, Berkeley, under Nobel laureate Melvin Calvin. He then was a research associate at the Ames Research Center from 1965 to 1966.
=== Conformational states === Simulations identified three distinct active-state conformational states of KOR: the canonical active state, an alternative state, and an occluded state. The alternative state, characterized by specific transmembrane domain conformations, correlates with β-arrestin2-biased signaling. The occluded state, in which the intracellular portion of transmembrane helix 7 rotates clockwise toward transmembrane helix 2, appears to favor G protein coupling whilst disfavoring β-arrestin recruitment. Specific residues within the receptor binding pocket differentially influence G protein versus β-arrestin signaling. Disruption of the ionic interaction by certain agonists increases the distance between the extracellular ends of transmembrane helices 5 and 6, contributing to ligand-specific transducer coupling preferences.
Sources: en.wikipedia.org
== Prognosis == The average progression rate from one stage of liver fibrosis to the next in those with MASH is estimated to be seven years. The course of progression varies with different clinical manifestations among individuals. Fibrosis in those with MASH progressed more rapidly than in those with MASLD. The risk of cirrhosis, liver cancer, liver-specific death, and overall death is higher in those with MASH as compared to MASLD. All-cause mortality in those with MASH is 25.5 deaths per 1000 person-years. Liver-specific mortality is 11.7 deaths per 1000 person-years. In one study that examined people over 15 years, 11% of those with MASH developed cirrhosis as compared to less than 1% of people with MASLD. Other estimates have shown that MASLD and MASH were found to worsen with cirrhosis in respectively 2–3% and 15–20% of the people over a 10–20 year period. Obesity predicts a worse long-term outcome than for lean individuals. In the Asia-Pacific region, about 25% of MASLD cases progress to MASH within three years, but only a low proportion (3.7%) develop advanced liver fibrosis. An international study showed that people with MASLD with advanced fibrosis had a 10-year survival rate of 81.5%. MASLD is a risk factor for liver fibrosis, hypertension, chronic kidney disease, atrial fibrillation, myocardial infarction, ischemic stroke, and death from cardiovascular causes based on very-low to low-quality evidence from observational studies. MASLD increases the risk of diabetes by 2.2 to 3.4 times.
=== Runoff and percolation === Solid bait and liquid insecticides, especially if improperly applied in a location, get moved by water flow. Often, this happens through nonpoint sources where runoff carries insecticides in to larger bodies of water. As snow melts and rainfall moves over and through the ground, the water picks applied insecticides and deposits them in to larger bodies of water, rivers, wetlands, underground sources of previously potable water, and percolates in to watersheds. This runoff and percolation of insecticides can effect the quality of water sources, harming the natural ecology and thus, indirectly effect human populations through biomagnification and bioaccumulation.
=== February === 1 February A ban on owning an American XL Bully dog comes into force in England and Wales. It is now a criminal offence to own one of the dogs unless the owner has successfully applied for the dog to be exempt. The Bank of England holds interest rates at 5.25%. Climate activist Greta Thunberg appears at Westminster Magistrates' Court, charged with breaching section 14 of the Public Order Act 1986. Her case, and that of four co-defendants, is thrown out the following day. COVID-19 vaccination in the United Kingdom: The first private service for COVID-19 vaccination begins rolling out to pharmacies around the UK, allowing those who are under 65 to receive the latest booster. 2 February Senior Labour MP Darren Jones confirms that the party has ditched its commitment to spend £28bn a year on green investment schemes if it wins the next general election. The killers of 16-year-old transgender girl Brianna Ghey are named as Scarlett Jenkinson and Eddie Ratcliffe, both aged 15 at the time of the murder in February 2023. They are sentenced at Manchester Crown Court to minimum terms of 22 and 20 years, respectively. Water UK, the umbrella trade organisation for the UK's water companies, says that the average annual water bill is expected to increase by 6% in England and Wales from April, an average rise of £27 to £473. 3 February 2024 Northern Ireland Executive formation: The Northern Ireland Assembly meets to elect a new Speaker. Edwin Poots, a former leader of the DUP, is chosen to be the Assembly's 7th Speaker.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.